Coherus Oncology, Inc. (CHRS)
Nasdaq · Healthcare · Biotechnology
$1.12−3.45%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $173M
- 52-week range
- $1.08 – $2.62
- 52-week change
- −32.16%
- EPS (trailing)
- −$1.20
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $42.2M (+59.81%)
- Net income
- $168M
- Operating margin
- −429.5%
- Diluted EPS
- $1.43
From the company’s annual report on SEC EDGAR.
About Coherus Oncology, Inc.
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME) patients with head and neck squamous cell carcinoma. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreements with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. It also has a clinical collaboration agreement with Zumutor Biologics Inc.
Headquarters: Redwood City, United States · 144 employees · coherus.com